[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dendreon\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100526399","phase-2-metastatic-castrate-resistant-prostate-cancer-subjects-treated-with-provenge--one-infusion-of-sipuleucel-t-100526399",false,"NCT06134232","Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T","An Open -Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With PROVENGE ® and Boosted With A Single Infusion of Sipuleucel-T to Measure Immune Response","ProvONE","Inclusion Criteria:\n\nFor a subject to be eligible for participation in this study, all of the following criteria must be satisfied:\n\n1. Potential subjects are men aged ≥18 years who are clinically indicated for treatment with PROVENGE® (asymptomatic or minimally symptomatic metastatic castrate-resistant \\[hormone refractory\\] prostate cancer).\n2. Have qualified for on-label PROVENGE® infusion\n3. Have received all 3 infusions of PROVENGE® prior to randomization\n4. Written informed consent provided prior to the initiation of study procedures\n5. Estimated life expectancy ≥12 months\n\nExclusion Criteria:\n\nA subject will not be eligible for participation in this study if any of the following criteria apply.\n\n1. Men who are not clinically indicated for treatment with PROVENGE® (asymptomatic or minimally symptomatic metastatic castrate-resistant \\[hormone refractory\\] prostate cancer).\n2. Need for systemic chronic immunosuppressive therapy, including antitumor necrosis factor alpha monoclonal antibodies, glucocorticoids, systemic steroids, blood products, GM-CSF or granulocyte colony-stimulating factor (G-CSF), any vaccinations, or experimental and investigational therapies (see Section 6.3.1)\n3. Uncontrolled, concurrent illness, including, but not limited to the following: ongoing or active infection (bacterial, viral, or fungal), or psychiatric illness that would limit compliance with study requirements, as well as any condition that would preclude a subject from completing PROVENGE® or sipuleucel-T treatment.\n4. On experimental or investigational therapy.","MALE","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).",[27],"Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[29,30,31,32,33],"Single Dose","Sipuleucel-T","Immune Response Rate","Safety","Adenocarcinoma of the Prostate","RECRUITING","2025-08-20",{"date":37,"type":38},"2025-08-27","ACTUAL",{"date":40,"type":38},"2023-10-02",{"date":42,"type":21},"2032-06-30",{"name":44,"class":45},"Dendreon","INDUSTRY",31,""]